ERYTECH to Participate in Upcoming Virtual Investor Conferences in March Lyon (France) and Cambridge, MA (U.S.), February 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
ERYTECH to Present at the 2021 BIO CEO & Investor Conference Lyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified,
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position Strong execution and achievement of key milestones in challenging year 2020 Four clinical programs with lead product candidate eryaspase expected to report results
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer Trial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic cancer Trial in Progress (TiP) poster accepted for
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH to Present at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event Lyon (France) and Cambridge, MA (U.S.), January 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
